Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis-Reference-Cited by-同舟云学术

Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis

Published:2021-05-01 Issue:4 Volume:479 Page:755-764
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Guy Alexandre^ORCID,Bidet Audrey,Ling Catherine,Caumont Charline,Boureau Lisa,Viallard Jean-François,Parrens Marie

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-021-03110-9.pdf

Reference31 articles.

1. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu S, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemiavera. Nature 434:1144–1148. https://doi.org/10.1038/nature03546

2. Levine RL, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly BJP, Boggon TJ, Wlodarska I, Clark J, Moore S, Adelsperger J, Koo S, Lee J, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa R, Tefferi A, Griffin J, Eck M, Sellers W, Meyerson M, Golub T, Lee S, Gilliland D (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397. https://doi.org/10.1016/j.ccr.2005.03.023

3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou G, Bench A, Boyd E, Curtin N, Scott M, Erber W, Green A (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061. https://doi.org/10.1016/S0140-6736(05)71142-9

4. Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Passweg J, Tichelli A, Cazzola M, Skoda R (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790. https://doi.org/10.1056/NEJMoa051113

5. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Azezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincoren I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O’Meara S, McLaren S, Bianchi M, Silver Y, Dimitropoulou D, Bloxhan D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du M-Q, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405. https://doi.org/10.1056/NEJMoa1312542

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistent hypersplenism following successful hematopoietic stem cell transplantation: unraveling the cellular components of extramedullary residual disease and donor hematopoiesis—a case report;Frontiers in Hematology;2024-01-09

2. JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions;Molecular Diversity;2023-11-25

3. Polystyrene micro-/nanoplastics induced hematopoietic damages via the crosstalk of gut microbiota, metabolites, and cytokines;Environment International;2022-03